{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-151729","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.170478+00:00","generated_at":"2026-06-01T07:13:14.771129+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aligos receives Nasdaq notice for Audit Committee noncompliance; cure period to Nov 2024","bullets":["Jack Nielsen resigned from Board and Audit Committee on May 21, 2024, causing noncompliance with Rule 5605.","Nasdaq granted cure period until Nov 18, 2024, as next annual meeting is June 27, 2024.","Company plans to appoint a third independent director to the Audit Committee before the cure deadline."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-151729","json":"https://secwatch.observer/filing/0001193125-24-151729.json","markdown":"https://secwatch.observer/filing/0001193125-24-151729.md","text":"https://secwatch.observer/filing/0001193125-24-151729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000119312524151729/0001193125-24-151729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000119312524151729/d808483d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:13:14.771129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}